The federal Project Grant award provides $1,151,250.00 to Texas A&M University System Health Science Center to develop a unique small molecule for triple-negative breast cancer. The grant is funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research initiatives to improve health outcomes for military service members, veterans, and the public. The award period runs from July 1, 2024 to June 30, 2027. Through this grant, Texas A&M University System Health Science Center will conduct innovative scientific research to develop a novel therapeutic approach for treating triple-negative breast cancer, a particularly aggressive form of the disease. The funding will enable the university's research team to carry out laboratory studies, preclinical testing, and potentially early-stage clinical trials to advance this promising small molecule therapy.